Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.52 |
| ▸ | SDCBP | O00560 | 6/20 | 0.50 |
| ▸ | SDC2 | P34741 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25331253 | 0.83 | ITGB3 (0.46) | THRBCASP3CASP7CASP9CASP6 | |
| SCHEMBL30477287 | 0.83 | ITGB3 (0.46) | THRBCASP3CASP7CASP9CASP6 | |
| SCHEMBL312310 | 0.82 | POLB (0.55) | KMT2ACASP3CASP7CASP9CASP6 | |
| SCHEMBL25331664 | 0.81 | MAPK1 (0.39) | SDCBPSDC2CASP3CASP7CASP9 | |
| SCHEMBL30477289 | 0.81 | MAPK1 (0.39) | SDCBPSDC2CASP3CASP7CASP9 | |
| SCHEMBL30477298 | 0.80 | MAPK1 (0.39) | SDCBPSDC2MEN1KMT2A | |
| SCHEMBL25330511 | 0.80 | SDCBP (0.38) | SDCBPSDC2CASP3 | |
| SCHEMBL30477316 | 0.80 | SDCBP (0.38) | SDCBPSDC2CASP3 | |
| SCHEMBL311793 | 0.78 | THRB (0.52) | THRBMEN1KMT2ACASP3CASP9 | |
| SCHEMBL25331706 | 0.77 | SDCBP (0.50) | SDCBPSDC2CASP3CASP7CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| US-7906650-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906650-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906650-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-15 | — | — | US | disclosed |
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | THRB 4677/4885SDCBP 4332/4885SDC2 4021/4885 |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | THRB 4677/4885SDCBP 4332/4885SDC2 4021/4885 |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | THRB 4677/4885SDCBP 4332/4885SDC2 4021/4885 |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP2 | THRB 4705/4885SDCBP 4008/4885SDC2 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.